Intrathecal pumps market is anticipated to grow at a significant CAGR of 6.1% during the forecast period. The rising incidence of chronic disorders, such as cancer, chronic pancreatitis, back pain, and others is significantly boosting the intrathecal pumps market across the globe during the forecast period. According to WHO, due to cancer around 10 million people died in 2020, and each year approximately 400,000 children develop cancer. Cancer pain remains undertreated, and a significant number of patients with cancer die while suffering from severe untreated pain every year, and with an increased survival rate for cancer patients, the occurrence of cancer pain is also rising. Pain occurs in 67% of patients with metastatic cancer and is the most prevalent symptom in patients. Intrathecal drug delivery pumps provide an alternate route of administration for analgesics, which may improve pain relief and decreases side effect, as it is a device that delivers small quantities of pain medication such as morphine or baclofen, directly to the spinal fluid. When these medicines are delivered in small doses, pain medications may minimize the side effects often experienced with larger oral doses of the same medications. Hence, the intrathecal pump is an effective pain management option for patients with chronic and cancer pain. 

Segmental Outlook 

The global intrathecal pumps market is segmented based on type, application, and end-user. Based on the type, the market is segmented into baclofen, bupivacaine, clonidine, morphine, ziconotide, and others. Based on application, the market is sub-segmented into spasticity and pain. Based on end-user, the market is segmented into hospitals & clinics, and ambulatory surgery centers. The above-mentioned segments can be customized as per the requirements.

Based on type the morphine segment is anticipated to grow at the fastest rate during the forecast period as morphine is considered more in intrathecal drug administration owing to its stability, strong receptor affinity, and extensive user experience of the drug. It is considered the classic opioid analgesic with which other painkillers are compared. Furthermore, long-term intrathecal morphine has fewer side effects as compared to systemic opioids, and also it has received approval for long-term intrathecal pain treatment by the US FDA. These strong factors are fuelling the morphine segment in the intrathecal pump market during the forecast period.

Regional Outlooks

The global intrathecal pumps market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America).  The market can be analyzed for a particular region or country level as per the requirement. North America is anticipated to grow at the fastest rate during the forecast period owing to different initiatives and projects to improve healthcare quality at an affordable cost in the US. North America spends more on healthcare needs than other regions, which is another factor contributing to market growth. For instance, in 2021 the North American Spine Society (NASS) developed coverage recommendations on spinal intrathecal delivery systems for the treatment of chronic pains. As per the North American Spine Society (NASS), the spinal intrathecal delivery system procedure may show an effect in a small group of people with chronic pain and spinal injury, this procedure supports people who have used all other options to treat their pain and symptoms. Hence boosting the market.

Global Intrathecal Pumps  Market Growth, by Region 2022-2028

The Asia-Pacific Region is Expected to Hold the Considerable Share in the Global Intrathecal Pumps Market 

The Asia-Pacific region is expected to hold a considerable share in the global intrathecal pumps market during the forecast period owing to the increasing number of pain care centers in China, Singapore, India, and Japan due to the rising aging population. Additionally, the high prevalence of pain-related disorders, increasing R&D expenditure, and the growing number of pain care centers in the region are boosting the demand for intrathecal pumps during the forecast period. For instance, Singapore Pain Care Center (SPCC) is a pain management center in Southeast Asia that provides an alternative to open surgery.  According to the US Census Bureau's latest data for 2022, Asia’s population is aging faster than any other world region, in 2020 the population of Asia-Pacific exceeded 4.5 billion (including China and India, the two countries with over 1 billion each), more than one-half the world’s total population, also there are an estimated 414 million Asian people age 65 and older, about 20% higher than the total US population (331.4 million). Moreover, by 2060 there will be more than 1.2 billion Asian people age 65 and older, which implies that one out of every 10 people in the world will be an older Asian. Hence, these old-age people will require these intrathecal pumps for medication as they are more prone to pain problems, which will directly boost the demand for these products.

Market Players Outlook

The major companies serving the global intrathecal pumps market include Flowonix Medical, Inc., Medical Device Business Services, Inc. (Johnson & Johnson), Teleflex, Inc., Tricumed Medizintechnik GmbH, Zimmer Biomet Holdings, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2022,  Flowonix Medical, Inc. partnered with Miratech Medical for the distribution of its targeted drug delivery products for the treatment of chronic pain and spasticity. Moreover, earlier in 2020 Flowonix Medical, Inc. got approval to market the Prometra II programmable pump system for use with intrathecal baclofen. Flowonix introduced the Prometra II 40mL pump to the US market in November 2019, providing patients and clinicians a choice between 20 mL and 40 mL capacities when choosing an intrathecal pump delivery device. The new indication expands significantly the market for the Prometra device by enabling its use in the treatment of spasticity.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global intrathecal pumps market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.